Vásquez FA, Cortez BR, Velarde CA, Guzmán HF, Morales CJ, Senado LI

Idioma: Español
Referencias bibliográficas: 22
Paginas: 261-266
Archivo PDF: 1143.14 Kb.

RESUMEN

La aplicación de la toxina botulínica es una modalidad de tratamiento relativamente nueva, inicialmente utilizada para propósitos cosméticos. Se le ha encontrado gran utilidad en otra variedad de patologías. En patología urinaria, se ha descrito su uso desde hace 15 años para la sobreactividad del detrusor, sin embargo, se continúan describiendo más aplicaciones de esta toxina. Este artículo pretende hacer una revisión de los beneficios de esta terapia para la urología.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Van Emergem E. Ueber einen neuen anaeroben Bacilus und Seine Beziehungen zum Botulismus. Zeitschrift fur Higiene und Infektionskrankheiten 26:1-56, 1897; traducción reimpresa en Rev Infect Dis. 1979; 1:701-719.

2. Horowitz BZ. Botulinum Toxin. Crit Care Clin. 2005; 21:825-39.

3. Shulte-Baukloh H, Weiss C, Stolze T et al. Botuli-num A toxin for the treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005;66:82-87.

4. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786-99.

5. Rajkumar GN, Conn IG. Botulinum toxin. A new dimension in the treatment of lower urinary tract dysfunction. Urology. 2004;65:211.

6. Hirst GR, Watkins AJ, Guerrero K,Wareham K, Emery SJ, Jones DR, Lucas MG. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology. 2007;69:69-73.

7. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68:1193-7.

8. Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology. 2005;66:865-70.

9. Kuo HC. Will suburothelial injection of small dose of botulinum toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006;68:993-8.

10. Schulte-Baukloh H, Bigalke H, Heine G, Pape D, Stuerzebecher B, Miller K, Knispel HH. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. Urology. 2007;69:575.

11. Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin-A on visceral sensory function in chronic spinal cord-injured rats. Urology. 2005;66:208-12.

12. Kuo HC. Prostate botulinum a toxin injection an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005;65: 670-4.

13. Zalvan C, Bentsianov B, Gonzalez-Yanes O, Blitzer A. Noncosmetic uses of botulinum toxin. Dermatol Clin. 2004;22:187-95.

14. Munchau A, Bhatia KB. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161-5.

15. Chancellor M. Treatment of interstitial cystitis. Urology. 2004;63:84-92.

16. Sangeeta T. Botulinum toxin: Form life-threatening disease to novel medical therapy. Am J Obstet. 2007; 196:7-15.

17. Mandell, Benett, Dolin. Principles and practice of infectious diseases. 6th edition, Churchill-Livingstone; chapter 243, 2005.

18. Cohen, Powderly. Infectious diseases, 2nd edition, Mosby, 2004.

19. Walsh. Campbell’s Urology, 8th edition, McGraw-Hill, 2004.

20. Moore C, Rackley R, Goldman H. Urologic applications of botox: Curr Urol Rep. 2005;6(6):419-23.

21. Hallet M. One man’s poison-Clinical applications of Botulinum toxin. N Engl J Med. 1999;341:118-20.

22. Karsenty G, Reitz A, Wefer B, Boy S, Schurch B. Understanding Detrusor sphincter dyssynergia significance of chronology. Urology. 2005;66:763-8.